377 related articles for article (PubMed ID: 35909534)
21. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
[TBL] [Abstract][Full Text] [Related]
22. Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.
Vilsbøll T; Lindahl CØ; Nielsen NF; Tikkanen CK
Diabetes Obes Metab; 2023 Jun; 25(6):1740-1749. PubMed ID: 36809678
[TBL] [Abstract][Full Text] [Related]
23. Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review.
Ruan Z; Jiang Y; Shi H; Jia R; Ung COL; Hu H
Expert Rev Clin Pharmacol; 2023 Feb; 16(2):161-176. PubMed ID: 36706368
[TBL] [Abstract][Full Text] [Related]
24. Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis.
Chen H; Li XZ; Chen JQ; Ren TS; Zhang YS; Wang YN; Zhao QC
Medicine (Baltimore); 2023 Jul; 102(27):e34122. PubMed ID: 37417602
[TBL] [Abstract][Full Text] [Related]
25. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.
Mody R; Huang Q; Yu M; Zhao R; Patel H; Grabner M; Landó LF
Diabetes Obes Metab; 2019 Apr; 21(4):920-929. PubMed ID: 30520248
[TBL] [Abstract][Full Text] [Related]
26. Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population.
Visaria J; Uzoigwe C; Swift C; Dang-Tan T; Paprocki Y; Willey VJ
Clin Ther; 2021 May; 43(5):808-821. PubMed ID: 33785221
[TBL] [Abstract][Full Text] [Related]
27. Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study.
Milenkovikj T; Chekorova Mitreva B; Jovanovska Mishevska S; Bitoska-Mileva I; Ahmeti I;
Diabetes Res Clin Pract; 2023 Dec; 206():111018. PubMed ID: 37972857
[TBL] [Abstract][Full Text] [Related]
28. Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.
Crabtree TSJ; Adamson K; Reid H; Barnes D; Sivappriyan S; Bickerton A; Gallen IW; Field BCT; Idris I; Ryder REJ;
Diabetes Obes Metab; 2022 Jul; 24(7):1398-1401. PubMed ID: 35322528
[TBL] [Abstract][Full Text] [Related]
29. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
Johansen P; Hunt B; Iyer NN; Dang-Tan T; Pollock RF
Adv Ther; 2019 May; 36(5):1190-1199. PubMed ID: 30875029
[TBL] [Abstract][Full Text] [Related]
30. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes.
Tuchscherer RM; Thompson AM; Trujillo JM
Ann Pharmacother; 2018 Dec; 52(12):1224-1232. PubMed ID: 29932006
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care.
von Arx LB; Rachman J; Webb J; Casey C; Patel A; Diomatari C; Wood R; Idris I
Diabetes Obes Metab; 2023 May; 25(5):1331-1340. PubMed ID: 36692268
[TBL] [Abstract][Full Text] [Related]
32. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella R; Pechtner V; Corcos A; Consoli A
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists.
Madsbad S; Holst JJ
Cardiovasc Res; 2023 May; 119(4):886-904. PubMed ID: 35925683
[TBL] [Abstract][Full Text] [Related]
34. Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients.
Marzullo P; Daffara T; Mele C; Zavattaro M; Ferrero A; Caputo M; Prodam F; Aimaretti G
J Endocrinol Invest; 2022 Aug; 45(8):1587-1598. PubMed ID: 35429298
[TBL] [Abstract][Full Text] [Related]
35. Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.
Fadini GP; Sciannameo V; Franzetti I; Bottigliengo D; D'Angelo P; Vinci C; Berchialla P; Arena S; Buzzetti R; Avogaro A;
Diabetes Obes Metab; 2019 Aug; 21(8):1886-1894. PubMed ID: 30985052
[TBL] [Abstract][Full Text] [Related]
36. Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase.
Seijas-Amigo J; Salgado-Barreira Á; Castelo-Dominguez R; Pérez-Álvarez MT; Ponce-Piñón B; Fernández-Silva M; Rodríguez-Barreiro M; Pereira-Pía M; Iglesias-Moreno JM; Gago-García M; Montáns-García R; Fernandez-Perez A; FragaGayoso D; Fernandez-Montenegro M; Riveiro-Barciela B; Rilla-Villar N; Cordero A; RodríguezMañero M; González-Juanatey JR
Prim Care Diabetes; 2023 Aug; 17(4):366-372. PubMed ID: 37230813
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Goldman JD
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
[TBL] [Abstract][Full Text] [Related]
38. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
39. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
